Gastric cancer is not a top‐10 malignancy in the United States but represents one of the
most common causes of cancer death worldwide. Biological differences between tumors …

The patients with high microsatellite instability (MSI-H)/mismatch repair deficient (dMMR)
tumors recently have been reported that can benefit from immunotherapy, and MSI can be …

Gastric cancer (GC) is a leading contributor to global cancer incidence and mortality.
Pioneering genomic studies, focusing largely on primary GCs, revealed driver alterations in …

PURPOSE In the CLASSIC and MAGIC trials, microsatellite instability (MSI)–high status was
a favorable prognostic and potential negative predictive factor for neoadjuvant/adjuvant …

Objective: To evaluate the short-term outcomes of patients with GC who received RDG or
LDG. Summary Background Data: Despite the increasing use of RDG in patients with GC, its …

Gastric cancer (GC) represents an important contributor to the global burden of cancer,
being one of the most common and deadly malignancies worldwide. According to TCGA and …

Background: A growing amount of evidence has suggested the clinical importance of
stromal and immune cells in the gastric cancer microenvironment. However, reliable …

Purpose We provide a comparison between 22C3 pharmDx and SP263 assay, for
evaluating programmed death ligand 1 (PD-L1) expression in advanced gastric cancer (GC) …

Gastric adenocarcinoma, even when diagnosed at an early (localized) disease stage, poses
a major health-care burden with cure rates that remain unsatisfactorily low, particularly in …

Opinion statement Gastric cancer is an aggressive malignancy, requiring a multimodality
approach to achieve optimal curative rates even when the disease is amenable to surgical …